Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia

Leukemia & Lymphoma
Carolyn OwenCarol Ward

Abstract

Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residual disease (MRD) is an important endpoint representing more accurately the depth of remission than complete response (CR), and is highly prognostic of progression-free survival (PFS) and overall survival (OS). MRD could be considered a key outcome of clinical trials and, as a surrogate for PFS, could identify the most cost-effective and durable treatment sequencing. MRD testing could also determine which patients would benefit from additional therapy and, accordingly, ascertain when therapy should be stopped earlier, to reduce toxicity and increase treatment-free intervals. Our article discusses possible uses of MRD in the modern era of CLL, including its definition, measurement, and value as a surrogate endpoint in clinical trials, and its potential roles in clinical practice.

References

Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul MoretonPeter Hillmen
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesc BoschEmili Montserrat
Jul 21, 2010·Developmental Cell·Daniel J Klionsky
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Committee
Aug 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G Wierda
Dec 17, 2016·OncoTargets and Therapy·Simona SerratìRosamaria Pinto

❮ Previous
Next ❯

Citations

Jan 17, 2020·HemaSphere·Moritz FürstenauMichael Hallek
Apr 26, 2020·International Journal of Laboratory Hematology·Alba MoraCarol Moreno
Dec 7, 2019·Hematology·Jacqueline CloosRichard Dillon
Dec 15, 2018·Cytometry. Part B, Clinical Cytometry·Adam C SeegmillerFiona E Craig
Jun 2, 2020·Clinical Case Reports·Ramya MuddasaniMarc Braunstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.